WallStreetZenWallStreetZen

NASDAQ: BLUE
Bluebird Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BLUE

Based on 4 analysts offering 12 month price targets for Bluebird Bio Inc

Min Forecast
$5.00+21.36%
Avg Forecast
$25.75+525%
Max Forecast
$80.00+1,841.75%

Should I buy or sell BLUE stock?

Based on 4 analysts offering ratings for Bluebird Bio Inc.

Buy
Strong Buy
1 analysts 25%
Buy
0 analysts 0%
Hold
3 analysts 75%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BLUE stock forecasts and price targets.

BLUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31
lockedlocked$00.00+00.00%2025-02-24
lockedlocked$00.00+00.00%2024-11-15
lockedlocked$00.00+00.00%2024-11-15

1 of 1

Forecast return on equity

Is BLUE forecast to generate an efficient return?

Forecast return on assets

Is BLUE forecast to generate an efficient return on assets?

Company
-3.4%
Industry
36.38%
BLUE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BLUE earnings per share forecast

What is BLUE's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$15.19
Avg 2 year Forecast
-$0.87

BLUE revenue forecast

What is BLUE's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$282.8M+237.44%
Avg 2 year Forecast
$412.1M+391.75%
BLUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BLUE revenue growth forecast

How is BLUE forecast to perform vs Biotechnology companies and vs the US market?

Company
65.55%
Industry
64.61%
Market
10.18%
BLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BLUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BLUE$4.12$25.75+525.00%Buy
BRNS$1.00$3.00+200.00%Buy
STTK$0.83$4.00+381.35%Buy
RVPH$0.88$8.25+840.71%Strong Buy
ESLA$1.10$16.00+1,361.19%Strong Buy
View Top Biotech Stocks

Bluebird Bio Stock Forecast FAQ

Is Bluebird Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BLUE) stock is to Buy BLUE stock.

Out of 4 analysts, 1 (25%) are recommending BLUE as a Strong Buy, 0 (0%) are recommending BLUE as a Buy, 3 (75%) are recommending BLUE as a Hold, 0 (0%) are recommending BLUE as a Sell, and 0 (0%) are recommending BLUE as a Strong Sell.

If you're new to stock investing, here's how to buy Bluebird Bio stock.

What is BLUE's earnings growth forecast for 2025-2026?

(NASDAQ: BLUE) Bluebird Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Bluebird Bio's earnings in 2025 is -$240,715,000.On average, 3 Wall Street analysts forecast BLUE's earnings for 2025 to be -$148,743,471, with the lowest BLUE earnings forecast at -$231,045,652, and the highest BLUE earnings forecast at -$41,118,294.

In 2026, BLUE is forecast to generate -$8,517,361 in earnings, with the lowest earnings forecast at -$8,517,361 and the highest earnings forecast at -$8,517,361.

What is BLUE's revenue growth forecast for 2025-2026?

(NASDAQ: BLUE) Bluebird Bio's forecast annual revenue growth rate of 65.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Bluebird Bio's revenue in 2025 is $83,807,000.On average, 1 Wall Street analysts forecast BLUE's revenue for 2025 to be $2,768,631,796, with the lowest BLUE revenue forecast at $2,768,631,796, and the highest BLUE revenue forecast at $2,768,631,796.

In 2026, BLUE is forecast to generate $4,034,683,648 in revenue, with the lowest revenue forecast at $4,034,683,648 and the highest revenue forecast at $4,034,683,648.

What is BLUE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BLUE) forecast ROA is -3.4%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is BLUE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year BLUE price target, the average BLUE price target is $25.75, with the highest BLUE stock price forecast at $80.00 and the lowest BLUE stock price forecast at $5.00.

On average, Wall Street analysts predict that Bluebird Bio's share price could reach $25.75 by Mar 31, 2026. The average Bluebird Bio stock price prediction forecasts a potential upside of 525% from the current BLUE share price of $4.12.

What is BLUE's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: BLUE) Bluebird Bio's current Earnings Per Share (EPS) is -$24.84. On average, analysts forecast that BLUE's EPS will be -$15.19 for 2025, with the lowest EPS forecast at -$23.60, and the highest EPS forecast at -$4.20. In 2026, BLUE's EPS is forecast to hit -$0.87 (min: -$0.87, max: -$0.87).

What is BLUE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BLUE) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.